
What is claimed is:

1. Use of a protein arginine N-methyl transferase 5 (PRMT5) inhibitor in the manufacture of a medicament for treating cancer in a subject, wherein:
a therapeutically effective amount of a taxane and a therapeutically effective amount of the PRMT5 inhibitor are to be administered to the subject, wherein the PRMT5 inhibitor is a compound of the formula



or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the cancer comprises methylthioadenosine phosphorylase (*MTAP*) gene homozygous deletion.


3. The use of claim 1 or 2, wherein the cancer further comprises a cyclin-dependent kinase inhibitor 2A (*CDKN2A*) gene homozygous deletion.

4. The use of any one of claims 1 to 3, wherein the cancer is lung cancer, pancreatic cancer, colon cancer, head and neck cancer, esophageal cancer, or melanoma.

5. The use of any one of claims 1 to 3, wherein the cancer is lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, esophageal cancer, lymphoma, stomach cancer, skin cancer, breast cancer, brain cancer, liver cancer, or colon cancer.

6. The use of any one of claims 1 to 3, wherein the cancer is lung cancer (e.g., mesothelioma or non-small cell lung cancer (NSCLC) including adenocarcinoma and squamous cell), pancreatic cancer, head and neck cancer, bladder cancer, esophageal cancer, lymphoma (e.g., diffuse large B-cell lymphoma), stomach cancer, melanoma, breast cancer, or brain cancer (e.g., glioblastoma multiforme and glioma).

7. The use of any one of claims 1 to 6, wherein the PRMT5 inhibitor is:



.

8. The use of any one of claims 1 to 7, wherein the therapeutically effective amount of the PRMT5 inhibitor is in the range of about 0.01 to 300 mg/kg per day.

9. The use of any one of claims 1 to 8, wherein the taxane comprises at least one of docetaxel, paclitaxel, abraxane, and cabazitaxel.

10. The use of claim 9, wherein the taxane is docetaxel.


11. The use of any one of claims 1 to 10, wherein the therapeutically effective amount of the taxane is in the range of about 1 to 500 mg/m^2 per day.

12. The use of any of claims 1 to 11, wherein the taxane and the PRMT5 inhibitor are to be administered sequentially, or wherein the taxane and the PRMT5 inhibitor are to be administered simultaneously.


13. The use of any one of claims 1 to 12, wherein the subject previously received or completed a first-line chemotherapy.

14. The use of claim 13, wherein the first-line chemotherapy is platinum- and/or taxane-based chemotherapy.

15. The use of claim 1, wherein the taxane is docetaxel having the formula:



; and

the PRMT5 inhibitor has the formula: 

.